Diclofenac transdermal second generation - Crescita Therapeutics

Drug Profile

Diclofenac transdermal second generation - Crescita Therapeutics

Alternative Names: Diclofenac sodium topical solution 2% w/w; MNK-395; NRI-1004; Pennsaid 2%; Pennsaid Gel; Pennsaid Plus; Pennsaid Viscous Solution

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator Nuvo Research
  • Developer Horizon Pharma; NovaMedica; Nuvo Research
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Musculoskeletal pain

Most Recent Events

  • 15 May 2017 Topline efficacy data from a phase III trial in Musculoskeletal pain released by Nuvo Pharmaceuticals
  • 10 May 2017 Nuvo Research completes the phase III (2016 Pennsaid 2% Trial for Musculoskeletal pain in Germany (9216223)
  • 28 Mar 2017 Diclofenac transdermal second generation licensed to Sayre Therapeutics in India, Nepal and Sri Lanka for the treatment of Osteoarthritis and Acute Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top